Your browser doesn't support javascript.
loading
Establishing the principle of reversibility in peptide/protein and small-molecule therapy.
Shechter, Yoram; Sasson, Keren; Marcus, Yonit; Rubinraut, Sara; Lev-Goldman, Vered; Fridkin, Mati.
Afiliación
  • Shechter Y; Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel. yoram.shechter@weizmann.ac.il
Ther Deliv ; 3(1): 17-23, 2012 Jan.
Article en En | MEDLINE | ID: mdl-22833930
ABSTRACT
Several important pharmacological features can be integrated into injected drugs to enhance their therapeutic efficacy following administration. Short-lived peptide/protein drugs should be converted into long-lived species in vivo to avoid multiple injections. Circulating levels of anticancer agents need to be maintained within a narrow therapeutic range for prolonged period. Water-insoluble drugs must be turned into soluble species and blood-brain barrier-impermeable agents need to be modified to cross it following peripheral administrations. The derivatization requiring for achieving those desirable pharmacological features typically result in biologically/pharmacologically inactive products, unless those derivatizations can be carried out in a reversible fashion.
Asunto(s)
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos / Proteínas Límite: Humans Idioma: En Revista: Ther Deliv Año: 2012 Tipo del documento: Article País de afiliación: Israel
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos / Proteínas Límite: Humans Idioma: En Revista: Ther Deliv Año: 2012 Tipo del documento: Article País de afiliación: Israel